US 12,331,279 B2
Systems for producing cellular immunotherapeutics and methods of use thereof
Shashi K. Murthy, Newton, MA (US)
Assigned to Northeastern University, Boston, MA (US)
Filed by Northeastern University, Boston, MA (US)
Filed on Aug. 10, 2023, as Appl. No. 18/448,031.
Application 18/448,031 is a continuation of application No. 17/664,532, filed on May 23, 2022, granted, now 11,767,500.
Application 17/664,532 is a continuation of application No. 15/970,664, filed on May 3, 2018, granted, now 11,371,008, issued on Jun. 28, 2022.
Application 15/970,664 is a continuation of application No. PCT/US2016/060701, filed on Nov. 4, 2016.
Claims priority of provisional application 62/250,618, filed on Nov. 4, 2015.
Claims priority of provisional application 62/250,630, filed on Nov. 4, 2015.
Prior Publication US 2023/0392106 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12M 1/36 (2006.01); A61K 39/00 (2006.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/45 (2025.01); C12M 1/00 (2006.01); C12M 1/02 (2006.01); C12M 1/26 (2006.01); C12M 1/42 (2006.01); C12M 3/06 (2006.01); C12N 5/0784 (2010.01)
CPC C12M 41/48 (2013.01) [A61K 39/0008 (2013.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/4524 (2025.01); C12M 23/16 (2013.01); C12M 23/28 (2013.01); C12M 27/00 (2013.01); C12M 29/04 (2013.01); C12M 33/00 (2013.01); C12M 35/08 (2013.01); C12M 41/14 (2013.01); C12N 5/0639 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/25 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A system for producing an immunotherapeutic product, the system comprising:
a first module configured for processing cellular material associated with a disease of a patient, the first module comprising a fluid inlet port and a separate fluid outlet port;
a second module configured for generating immune cells, the second module comprising a cell culture chamber, a fluid inlet port, and a separate fluid outlet port disposed on opposite sides of the cell culture chamber, the separate fluid outlet port positioned at a height above the fluid inlet port, wherein the cell culture chamber comprises a monocyte-binding substrate, and wherein the fluid inlet port and the separate fluid outlet port are fluidically coupled to the cell culture chamber and configured to provide flow of a liquid culture medium across the monocyte-binding substrate from the fluid inlet port to the separate fluid outlet port that minimizes mechanical detachment of cells from the monocyte-binding substrate; and
a third module separately coupled to and in fluidic communication with each of the first and second modules, the third module comprising a first inlet port for fluidic communication with the first module and a separate second inlet port for fluidic communication with the second module such that the third module separately receives a flow of processed cellular material from the first module and separately receives a flow of immune cells from the second module, wherein the third module is configured to co-culture the processed cellular material and the immune cells to produce an immunotherapeutic product.